SD 1008Inhibitor of JAK2/STAT3 signaling pathway,apoptosis inducer CAS# 960201-81-4 |
- CYT387 sulfate salt
Catalog No.:BCC1506
CAS No.:1056636-06-6
- Baricitinib phosphate
Catalog No.:BCC1401
CAS No.:1187595-84-1
- JAK2 Inhibitor V, Z3
Catalog No.:BCC1667
CAS No.:195371-52-9
- Bardoxolone methyl
Catalog No.:BCC1400
CAS No.:218600-53-4
- Ruxolitinib (INCB018424)
Catalog No.:BCC1276
CAS No.:941678-49-5
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 960201-81-4 | SDF | Download SDF |
| PubChem ID | 90488797 | Appearance | Powder |
| Formula | C18H19NO5 | M.Wt | 329.35 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble to 100 mM in DMSO and to 5 mM in ethanol | ||
| Chemical Name | dimethyl (1R,5R,6R,7S)-8-benzyl-4-oxo-8-azabicyclo[3.2.1]oct-2-ene-6,7-dicarboxylate | ||
| SMILES | COC(=O)C1C2C=CC(=O)C(C1C(=O)OC)N2CC3=CC=CC=C3 | ||
| Standard InChIKey | PYZQFEIRZQYUJQ-MIGQKNRLSA-N | ||
| Standard InChI | InChI=1S/C18H19NO5/c1-23-17(21)14-12-8-9-13(20)16(15(14)18(22)24-2)19(12)10-11-6-4-3-5-7-11/h3-9,12,14-16H,10H2,1-2H3/t12-,14-,15-,16+/m1/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | JAK2/STAT3 signaling pathway inhibitor. Inhibits activation of STAT3, JAK2 and Src. Induces apoptosis in cell lines expressing constitutively active tyrosine-phosphorylated STAT3. |
SD 1008 Dilution Calculator
SD 1008 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 3.0363 mL | 15.1814 mL | 30.3628 mL | 60.7257 mL | 75.9071 mL |
| 5 mM | 0.6073 mL | 3.0363 mL | 6.0726 mL | 12.1451 mL | 15.1814 mL |
| 10 mM | 0.3036 mL | 1.5181 mL | 3.0363 mL | 6.0726 mL | 7.5907 mL |
| 50 mM | 0.0607 mL | 0.3036 mL | 0.6073 mL | 1.2145 mL | 1.5181 mL |
| 100 mM | 0.0304 mL | 0.1518 mL | 0.3036 mL | 0.6073 mL | 0.7591 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
SD 1008 is reported to be a JAK2/STAT3 signaling pathway inhibitor which additionally inhibits Src. SD 1008 is noted to induce apoptosis in cell lines that express constitutively active tyrosine-phosphorylated STAT3.
- 2-hexyl-4-Pentynoic Acid
Catalog No.:BCC6480
CAS No.:96017-59-3
- Mepivacaine
Catalog No.:BCC9020
CAS No.:96-88-8
- Aminothiazole
Catalog No.:BCC4623
CAS No.:96-50-4
- Guajadial
Catalog No.:BCN4509
CAS No.:959860-49-2
- CH5138303
Catalog No.:BCC5364
CAS No.:959763-06-5
- Guggulsterone Z
Catalog No.:BCN3793
CAS No.:95975-55-6
- TC-E 5005
Catalog No.:BCC6227
CAS No.:959705-64-7
- 5,7,4-Trihydroxy-3,6-dimethoxy-3-prenylflavone
Catalog No.:BCN1297
CAS No.:959421-20-6
- 4-Hydroxyalternariol 9-methyl ether
Catalog No.:BCN7389
CAS No.:959417-17-5
- PF 750
Catalog No.:BCC7641
CAS No.:959151-50-9
- A922500
Catalog No.:BCC2333
CAS No.:959122-11-3
- 2-Benzoylacetanilide
Catalog No.:BCC8560
CAS No.:959-66-0
- Vortioxetine (Lu AA21004) HBr
Catalog No.:BCC1213
CAS No.:960203-27-4
- Meropenem
Catalog No.:BCC2489
CAS No.:96036-03-2
- ONX-0914 (PR-957)
Catalog No.:BCC2095
CAS No.:960374-59-8
- Jatrorrhizine Hydrochloride
Catalog No.:BCC8193
CAS No.:960383-96-4
- ent-17-Hydroxykauran-3-one
Catalog No.:BCN4510
CAS No.:960589-81-5
- Massoniresinol
Catalog No.:BCN4511
CAS No.:96087-10-4
- Stylopine hydrochloride
Catalog No.:BCN6964
CAS No.:96087-21-7
- 2'-Deoxyguanosine
Catalog No.:BCC5433
CAS No.:961-07-9
- Isoliquiritigenin
Catalog No.:BCN4512
CAS No.:961-29-5
- MPEP
Catalog No.:BCC4594
CAS No.:96206-92-7
- Epidermal Growth Factor Receptor Peptide (985-996)
Catalog No.:BCC1014
CAS No.:96249-43-3
- Methyl 8-hydroxy-3-(2-methoxy-2-oxoethyl)-6-methyl-9-oxo-9H-furo[3,4-b]chromene-1-carboxylate
Catalog No.:BCN7465
CAS No.:96287-41-1
8-benzyl-4-oxo-8-azabicyclo[3.2.1]oct-2-ene-6,7-dicarboxylic acid (SD-1008), a novel janus kinase 2 inhibitor, increases chemotherapy sensitivity in human ovarian cancer cells.[Pubmed:17675586]
Mol Pharmacol. 2007 Nov;72(5):1137-45.
Interleukin 6 and the signal transducer and activator of transcription (STAT) 3 proteins have important roles in cancer cell survival and proliferation. Recent studies demonstrate that abnormal STAT3 activation promotes tumor growth and supports survival of many human cancers, and thus, this protein or the pathway responsible for its activation is a potential target for the new anticancer therapy. STAT3 is a DNA binding transcription factor, and therefore, its function depends on nuclear translocation. To discover inhibitors of the STAT3 pathway, we designed a cell-based screening assay capable of identifying small molecules that inhibit nuclear translocation. Among the 2000-compound National Cancer Institute Diversity set, we identified 8-benzyl-4-oxo-8-azabicyclo[3.2.1]oct-2-ene-6,7-dicarboxylic acid (SD-1008) as a micromolar inhibitor of interleukin-6 or oncostatin-induced STAT3 nuclear translocation. In addition, SD-1008 inhibits tyrosyl phosphorylation of STAT3, Janus kinase 2 (JAK2), and Src. SD-1008 also reduces STAT3-dependent luciferase activity. Biochemical studies with recombinant JAK2 proteins demonstrate that high concentrations of SD-1008 directly inhibit JAK2 kinase autophosphorylation. Exposure of various cell lines to SD-1008 decreases levels of the STAT3-dependent proteins, Bcl-X(L) and survivin, inducing apoptosis. SD-1008 also enhances apoptosis induced by paclitaxel in ovarian cancer cells. These results demonstrate that SD-1008 directly blocks the JAK-STAT3 signaling pathway in human cancer cells that express constitutively active Stat and add to the growing literature that identifies this pathway as a viable target for drug development. Finally, SD-1008 may be a suitable prototype for further chemical modification and exploration as a therapeutic agent.
